| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.04857-14 |
| P8608 | Fatcat ID | release_ayjkrp6hwbbslcnjhz3dpcqofe |
| P932 | PMC publication ID | 4394786 |
| P698 | PubMed publication ID | 25753643 |
| P50 | author | Nathan Paul Wiederhold | Q42104169 |
| Thomas F Patterson | Q56859142 | ||
| Laura K. Najvar | Q115923764 | ||
| Rosie A Bocanegra | Q115923770 | ||
| William R. Kirkpatrick | Q122227392 | ||
| P2093 | author name string | Brian L Wickes | |
| Satoru Matsumoto | |||
| Nathan P Wiederhold | |||
| Monica L Herrera | |||
| P2860 | cites work | Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus | Q21972844 |
| Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome | Q24811601 | ||
| Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits | Q28369150 | ||
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate | Q33983618 | ||
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 | ||
| Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| Standardization of an experimental murine model of invasive pulmonary aspergillosis | Q35091545 | ||
| Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. | Q35138937 | ||
| The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy | Q35185757 | ||
| Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. | Q36482821 | ||
| Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis. | Q36559047 | ||
| Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture | Q36744831 | ||
| Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. | Q36987908 | ||
| Strain-dependent variation in 18S ribosomal DNA Copy numbers in Aspergillus fumigatus | Q37191546 | ||
| Paradoxical echinocandin activity: a limited in vitro phenomenon? | Q37405284 | ||
| Novel inhalational murine model of invasive pulmonary aspergillosis | Q37734691 | ||
| The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro | Q39652699 | ||
| Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition | Q42707146 | ||
| Cyclophosphamide metabolism is affected by azole antifungals | Q43530745 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants | Q44606439 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis | Q46265389 | ||
| Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | Q51187346 | ||
| Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum | Q56838501 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 2875-2881 | |
| P577 | publication date | 2015-03-09 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis | |
| P478 | volume | 59 |
| Q37344546 | A complex game of hide and seek: the search for new antifungals |
| Q97525325 | Caenorhabditis elegans-Based Aspergillus fumigatus Infection Model for Evaluating Pathogenicity and Drug Efficacy |
| Q92575576 | Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus |
| Q92970856 | In vitro and in vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus fumigatus |
| Q55511181 | Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. |
| Q33689767 | Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization. |
| Q38796140 | Systemic Antifungal Agents: Current Status and Projected Future Developments. |
Search more.